TAC1 (tachykinin, precursor 1)

2009-06-01   Philip K Lim  , Shyam A Patel  , Pranela Rameshwar  

University of Medicine, Dentistry of New Jersey - New Jersey Medical School,Newark, New Jersey, USA

Identity

HGNC
LOCATION
7q21.3
LOCUSID
ALIAS
Hs.2563,NK2,NKNA,NPK,TAC2

DNA/RNA

Description

The TAC1 gene maps (Homo sapiens) to NC_000007.12 in the region between 97199311 and 97207720 on the plus strand and spans 8410 bp.

Transcription

4 transcript variants:
alpha (1134 bp); open reading frame from bp 247-582
-lacks exon 6
-encodes substance P on exon 3
beta (1188 bp); open reading frame from bp 247-636
-encodes the full-length version of Tac1
-encodes substance P, neurokinin A, neuopeptide K
delta (1089 bp); open reading frame from bp 247-537
-lacks exons 4 and 6
-encodes substance P on exon 3
gamma (1143 bp); open reading frame from bp 247-591
-lacks exon 4
-encodes substance P, neurokinin A

Proteins

Note

The TAC1 gene encodes multiple transcripts through post-translational modifications. Each encodes peptides belonging to the tachykinin family of peptides. The major peptides produced from the TAC1 transcripts are substance P and neurokinin A. Others include neuropeptide K, and neuropeptide gamma. The tachykinins exert multiples functions such as neurotransmission, immune modulation and hematopoietic regulation. TAC1 encodes peptides that target nerve receptors, immune cells, stem cells, hematopoietic cells and smooth muscle cells. They function in vasodilatory responses; act as secretagogues and can induce behavioral responses.

Description

4 peptides:
alpha: 111 aa
-comprises substance P
beta: 129 aa
-comprises substance P, neurokinin A, neuropeptide K
delta: 96 aa
-comprises substance P
gamma: 114 aa
-comprises neuropeptide gamma, substance P, neurokinin A.

Expression

Expressed by various immune and neuronal cells.
TAC1 expression in the setting of osteoarthritis can be induced by mechanical stimulation (Howard et al., 2008).
TAC1 expression is also regulated by microRNAs in neurons derived from human mesenchymal stem cells (Greco et al., 2007). This occurs by binding of miRNA-13-a, miRNA206 and miRNA302a to the Tac1 3UTR.
HIV1 infection resulted in increase production of TAC1 peptide (substance P). The source of substance P has been identified as monocytes-derived macrophages from placenta cord blood and adult peripheral blood. The production of substance P correlates with HIV 1 infection (Douglas et al., 2002).

Localisation

Secreted peptide.

Function

TAC1 peptides function in both pathologic and physiologic processes. These include hematopoiesis, gastrointestinal secretory processes, respiratory patterns, calcium signaling, neuropeptide signaling, pain, synaptic transmission, insemination (Murthy et al., 2008; David et al., 2009); inflammatory response, autism, and pulmonary infection (Marui et al., 2007; Grissell et al., 2007).
In normal respiratory development, TAC1 appears to be a crucial gene, exerting plasticity during development (Berner et al., 2007).
TAC1 is involved in hematopoietic regulation. The mRNA is targeted by RNA-binding protein that confers translational control, which could be negatively regulated by cytokines with hematopoietic stimulator properties (Murthy et al., 2008).
TAC1 has been implicated in macrophage and monocyte functions (Chernova et al., 2009).

Homology

Homo sapiens TAC1 shares sequence homology with mouse and rat sequences.

Implicated in

Entity name
Breast Cancer
Note
A gene expression signature for breast cancer has been shown to involve TAC1 (Ellsworth et al., 2009).
Prognosis
TAC1 expression occurs in breast cancer and is directly proportional to aggressiveness of the cancer and thus, TAC1 may also be a prognostic factor in breast cancer (Ellsworth et al., 2009; Reddy et al., 2009).
Oncogenesis
TAC1 expression favors breast cancer cell entry into the bone marrow during stage IV disease (Reddy et al., 2009). TAC1 regulates the interaction between CXCL12 and its receptor, CXCR4 in the interaction between breast cancer and mesenchymal stem cells (Corcoran et al., 2008).
The TAC1 gene products, substance P and neurokinin A, and neurokinin receptor antagonists have been shown to have anti-proliferative effects on breast cancer cells (Rameswhar et al., 1996; Singh et al., 2000).
Entity name
Colon cancer
Note
Substance P, the major peptide encoded by the TAC1 gene, is mitogenic to colon cancer. Its action on the cancer cells appears to be autocrine since NK1 antagonist has been shown to mediate anti-tumor activity (Rosso et al., 2008). On the other hand, Substance P also enhances the expansion of lymphokine-activated killer cells against colon cancer cells (Flageole et al., 1992). These two properties of substance P appear paradoxical. Thus, targeted therapy will need to balance the immune-enhancing effects with the tumor promoting functions of substance.
Prognosis
In Dukes stage A/B cancers, TAC1 methylation levels were significantly higher than in Dukes stage C/D cancers (Mori et al., 2006).
Oncogenesis
TAC1 was found to be silenced via promoter methylation in primary colon cancer and may lead to early stage carcinogenesis by aiding tumor cells to escape immune surveillance and autocrine growth-inhibitory signaling (Mori et al., 2006).
Entity name
Esophageal cancer
Prognosis
Promoter hypermethylation of TAC1 confers poor prognosis in esophageal cancer (Jin et al., 2007).
Oncogenesis
TAC1 promoter hypermethylation has been suggested to be a putative marker for esophageal carcinoma (Jin et al., 2007).
Entity name
Gastric adenocarcinoma
Oncogenesis
Promoter hypermethylation of TAC1 has also been found in gastric adenocarcinoma (David et al., 2009).
Entity name
Multiple Sclerosis
Note
The genetic region surrounding TAC1 may be unstable and has been associated with increased susceptibility to multiple sclerosis (Vandenbroeck et al., 2002).
Entity name
Narcolepsy
Note
TAC1 and other related peptides have been associated with narcolepsy. Stimulation by amphetamines promotes increased TAC1 expression (Lindberg et al., 2007).

Article Bibliography

Pubmed IDLast YearTitleAuthors

Other Information

Locus ID:

NCBI: 6863
MIM: 162320
HGNC: 11517
Ensembl: ENSG00000006128

Variants:

dbSNP: 6863
ClinVar: 6863
TCGA: ENSG00000006128
COSMIC: TAC1

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000006128ENST00000319273P20366
ENSG00000006128ENST00000346867P20366
ENSG00000006128ENST00000350485P20366

Expression (GTEx)

0
50
100
150
200

Pathways

PathwaySourceExternal ID
Signal TransductionREACTOMER-HSA-162582
Signaling by GPCRREACTOMER-HSA-372790
GPCR ligand bindingREACTOMER-HSA-500792
Class A/1 (Rhodopsin-like receptors)REACTOMER-HSA-373076
Peptide ligand-binding receptorsREACTOMER-HSA-375276
Tachykinin receptors bind tachykininsREACTOMER-HSA-380095
GPCR downstream signalingREACTOMER-HSA-388396
G alpha (q) signalling eventsREACTOMER-HSA-416476
Gastrin-CREB signalling pathway via PKC and MAPKREACTOMER-HSA-881907

Protein levels (Protein atlas)

Not detected
Low
Medium
High

References

Pubmed IDYearTitleCitations
378529382024The role of calcitonin gene-related peptide and substance P in the pathogenesis of dialysis headache.0
379315112024Substance P, NPY, CCK and their receptors in five brain regions in major depressive disorder with transcriptomic analysis of locus coeruleus neurons.2
383767472024Neural Circuitry Involving Substance P in Male Sexual Behavior.0
378529382024The role of calcitonin gene-related peptide and substance P in the pathogenesis of dialysis headache.0
379315112024Substance P, NPY, CCK and their receptors in five brain regions in major depressive disorder with transcriptomic analysis of locus coeruleus neurons.2
383767472024Neural Circuitry Involving Substance P in Male Sexual Behavior.0
364617992023Concentration of substance P in patients with atopic dermatitis with and without past history of treatment.0
365494662023Temporospatial Expression of Neuropeptide Substance P in Dental Pulp Stem Cells During Odontoblastic Differentiation in Vitro and Reparative Dentinogenesis in Vivo.2
365495782023Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction.5
366516052023The neuropeptide substance P/neurokinin-1 receptor system and diabetes: From mechanism to therapy.1
371325952023The Role of Substance P Within Traumatic Brain Injury and Implications for Therapy.0
374081822023Involvement of Substance P (SP) and Its Related NK1 Receptor in Primary Sjögren's Syndrome (pSS) Pathogenesis.0
379446182023Deciphering specificity and cross-reactivity in tachykinin NK1 and NK2 receptors.0
364617992023Concentration of substance P in patients with atopic dermatitis with and without past history of treatment.0
365494662023Temporospatial Expression of Neuropeptide Substance P in Dental Pulp Stem Cells During Odontoblastic Differentiation in Vitro and Reparative Dentinogenesis in Vivo.2

Citation

Philip K Lim ; Shyam A Patel ; Pranela Rameshwar

TAC1 (tachykinin, precursor 1)

Atlas Genet Cytogenet Oncol Haematol. 2009-06-01

Online version: http://atlasgeneticsoncology.org/gene/44483/gene-explorer/img/tumors-explorer/